The recent development of quantitative MRI biomarkers, describing muscle atrophy and muscle fat replacement, has proven that the effect of disease activity in NMD (Neuromuscular Disorders) can be detected earlier and more precisely when compared to methods aiming at describing functional decline. Learn more from AMRA Medical Research and guest speakers from Fulcrum and Pfizer in our upcoming webinar. Are you interested to register for this webinar? Click on the register button below!